Is MiNK Therapeutics going out of business?

MiNK Therapeutics, Inc. (INKT) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

MiNK Therapeutics, Inc. (INKT) scores 15 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Interest coverage: -199.8x

Five questions, kept separate

Survival - Fragile

7-11 mo of estimated runway from 2026-06-30, based on $8.8M of cash and short-term investments against $11.5M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Balanced

26.1% burn burden support a balanced pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Interest coverage: -199.8x
• Filing event risk: Going-Concern Warning (-8 pts)
• Shares dilution YoY: 23.60% (YoY)
• Return on Assets: -129.94%
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-13.

Price as of 2026-09-07.